Ventral hernias after cytoreductive surgery: how often they occur and how they are managed.
Official title: Incidence, Risk Factors and Surgical Management of Incisional Hernias Following Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Monocentric Cohort Study
Run by Jules Bordet Institute · NCT07451483 · Data updated 2026-11-12
This retrospective review tries to find how often adults who had cytoreductive surgery with or without HIPEC develop ventral hernias and which factors are linked to them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Jules Bordet Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Anderlecht, Brussels Capital) |
| Status | Recruiting |
| Started | January 20, 2026 |
| Main results expected | February 28, 2026 |
| Study ends | March 2026 |
| Registry record updated | March 5, 2026 |
| Trial ID | NCT07451483 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who underwent CRS ± HIPEC for pseudomyxoma peritonei, colorectal, or ovarian peritoneal carcinomatosis between January 1, 2010 and December 31, 2024 with complete records and at least one year of follow-up.
✕Probably not a fit
Patients with a prior ventral hernia at the planned incision site, those treated for primary cancers other than PMP/colorectal/ovarian peritoneal carcinomatosis, or those with incomplete records or under one year of follow-up are excluded and may not benefit from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective observational review of adult patients treated with cytoreductive surgery (CRS) with or without HIPEC for pseudomyxoma peritonei, colorectal, or ovarian peritoneal carcinomatosis between 2010 and 2024 at a single center. Investigators will extract data from medical records to determine the incidence of postoperative ventral (incisional) hernias, identify associated patient- and surgery-related risk factors, and describe how hernias were managed surgically. No prospective interventions or follow-up are performed; cases with incomplete records or under one year of follow-up are excluded. The goal is to clarify rates and management patterns to inform future prevention and treatment strategies.
Why it matters
Potential benefit: If successful, the findings could help clinicians identify patients at higher risk of ventral hernia after CRS ± HIPEC and inform follow-up, preventive measures, or timing/approach to repair to reduce morbidity.
How similar studies have gone: Previous single-center and retrospective series have reported widely varying hernia rates and suggested some risk factors, so this work builds on existing data but addresses persistent uncertainties rather than introducing a novel intervention.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients (≥18 years) who underwent CRS +/- HIPEC for PMP, colorectal and ovarian PC between 01 January 2010 and 31 December 2024. Exclusion Criteria: * Patients with a prior history of ventral hernia at the planned incision site. * Patients undergoing CRS +/- HIPEC for primary cancer other than PMP, colorectal and ovarian PC. * Patients with incomplete medical records preventing data extraction. * Patients lost to follow-up within one year of surgery.
Where it's running
-
Jules Bordet Institute
Anderlecht, Brussels Capital, Belgium Recruiting
Study contacts
- Principal investigator: Gabriel Liberale, MD, Phd — Jules Bordet Institute
- Study coordinator: Gabriel Pr. Liberale, MD, PhD
- Email: gabriele.liberale@hubruxelles.be
- Phone: +32 477606766
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Removing most of the stomach tumor after chemotherapy versus chemotherapy alone for limited metastatic stomach cancer
This trial will test whether removing most of the stomach tumor after initial systemic therapy helps people with limited metastatic stomach cancer live longer than systemic therapy alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.